Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.

@article{lvarezLajonchere2009ImmunogenicityOC,
  title={Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.},
  author={Liz {\'A}lvarez-Lajonchere and Naglaa H Shoukry and Bienvenido Gr{\'a} and Yalena Amador-Ca{\~n}izares and Francois Helle and Nathalie B{\'e}dard and Ines M. Guerra and Christian Allen Drouin and Jean Dubuisson and Eddy E Gonz{\'a}lez-Horta and Gillian Mart{\'i}nez and Jeny Marante and Zurina Cinza and Marlen Castellanos and Santiago Due{\~n}as-Carrera},
  journal={Journal of viral hepatitis},
  year={2009},
  volume={16 3},
  pages={156-67}
}
SUMMARY Hepatitis C virus (HCV) is a worldwide health problem. No vaccine is available against this pathogen and therapeutic treatments currently in use are of limited efficacy. In the present study, the immunogenicity of the therapeutic vaccine candidate CIGB-230, based on the mixture of pIDKE2, a plasmid expressing HCV structural antigens, with a recombinant HCV core protein, Co.120, was evaluated. CIGB-230 was administered by intramuscular injection on weeks 0, 4, 8, 12, 16 and 20 to 15 HCV… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…